Home » Newsletters » BioWorld Science

BioWorld Science

July 27, 2022

View Archived Issues

CFB inhibitors identified by Shanghai Hengrui Pharmaceutical, Jiangsu Hengrui Medicine

ScinnoHub Pharmaceutical discovers plasmin inhibitors

Discovery of novel candidates for the treatment of Chagas disease

Impact Biomedical announces development of Quantum antihistamine

SBIR grant supports STRM.BIO's development of EV technology as gene therapy delivery platform

ExcellGene plays role in CEPI-funded consortium to advance new vaccine concept for SARS-CoV-2

Medshine Discovery describes new complement factor B inhibitors

C-65780 stabilizes voltage-gated sodium channels and produces pain relief in vivo

Suzhou Zelgen Biosciences identifies new aryl hydrocarbon receptor antagonists

New MAT2A inhibitors discovered at Jiangsu Simcere Pharmaceutical R&D

Monoclonal antibody pairs "zipper" to target cancer

Amubarvimab/romlusevimab retains neutralizing activity against live Omicron subvariants

Vitamin B6 benzohydrazide platinum(II) complexes overcome cisplatin resistance in tumors

ZyVersa receives grant to assess potential of IC-100 to block neuroinflammation in Parkinson's

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 23, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
Psychedelic space expanding on Trump’s EO
BioWorld
Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...